Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.
about
Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) systemPatient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.Dysuria Following Stereotactic Body Radiation Therapy for Prostate CancerThe effect of body contouring on the dose distribution delivered with volumetric-modulated arc therapy technique.Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
P2860
Q33672832-4966DF58-F8E9-4C40-B158-B13E65952B1DQ33851417-780E4BAA-46D2-45F7-8290-F3F63B71A949Q33985573-18CB8D84-97A4-4C2F-A5B3-CCB9C207A455Q35174871-948827BA-0185-4253-A2C5-BC3079E60A43Q35515150-D9022020-B47E-41AD-99AB-98911EE52D18Q36023165-7AA9B056-E2D2-4EE5-864A-8B72B3A70DF6Q36722591-F4299A48-9085-4E5A-8BF8-23049A2AD431Q37702326-156C659D-0990-47C4-AEEF-0CACD6C5102FQ38550590-194A246E-3101-4D28-9700-7929B870211CQ40176306-582DAF49-7B84-4417-9AFE-4305D0595A47Q41821780-D4D96491-62BC-4B4B-9D85-910DE6DF3176Q42953465-D04775C1-8A60-492D-973C-F24EED9DD223Q55379685-3B5CF43B-5611-4AFA-9201-B8D14A0905DF
P2860
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Randomized phase II trial of u ...... mplications for focal therapy.
@ast
Randomized phase II trial of u ...... mplications for focal therapy.
@en
type
label
Randomized phase II trial of u ...... mplications for focal therapy.
@ast
Randomized phase II trial of u ...... mplications for focal therapy.
@en
prefLabel
Randomized phase II trial of u ...... mplications for focal therapy.
@ast
Randomized phase II trial of u ...... mplications for focal therapy.
@en
P2093
P2860
P356
P1433
P1476
Randomized phase II trial of u ...... implications for focal therapy
@en
P2093
Charlie Pan
Dale W Litzenberg
Daniel A Hamstra
Eyad Abu-Isa
Howard M Sandler
Jeffrey Vainshtein
Karin B Olson
Kathryn Masi
Michael E Ray
P2860
P2888
P356
10.1186/1748-717X-7-82
P577
2012-06-09T00:00:00Z
P6179
1024271356